• Quadriparesis and paraparesis are rare toxicities seen after CART therapy in children.

  • The mechanism of post-CART paresis is likely complex but not clearly inflammatory based on autopsy, CSF flow cytometry, or proteomic data.

Abstract

Immune effector cell–associated neurotoxicity syndrome (ICANS) is a common but potentially severe adverse event associated with chimeric antigen receptor T-cell (CART) therapy, characterized by the development of acute neurologic symptoms following CART infusion. ICANS encompasses a wide clinical spectrum typified by mild to severe encephalopathy, seizures, and/or cerebral edema. As more patients have been treated with CART, new ICANS phenomenology has emerged. We present the clinical course of 5 children who developed acute onset of quadriparesis or paraparesis associated with abnormal brain and/or spine neuroimaging after infusion of CD19- or CD22-directed CART, adverse events not previously reported in children. Orthogonal data from autopsy studies, cerebrospinal fluid (CSF) flow cytometry, and CSF proteomics/cytokine profiling demonstrated chronic white matter destruction, but a notable lack of inflammatory pathologic changes and cell populations. Instead, children with quadriparesis or paraparesis post-CART therapy had lower levels of proinflammatory cytokines, such as interferon gamma, CCL17, CCL23, and CXCL10, than those who did not develop quadriparesis or paraparesis. Taken together, these findings imply a noninflammatory source of this newly described ICANS phenomenon in children. The pathophysiology of some neurologic symptoms following CART may therefore have a more complex etiology than exclusive T-cell activation and excessive cytokine production.

1.
Lee
DW
,
Santomasso
BD
,
Locke
FL
, et al
.
ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells
.
Biol Blood Marrow Transplant
.
2019
;
25
(
4
):
625
-
638
.
2.
Reagan
PM
,
Neelapu
SS
.
How I manage: pathophysiology and management of toxicity of chimeric antigen receptor T-cell therapies
.
J Clin Oncol
.
2021
;
39
(
5
):
456
-
466
.
3.
Norelli
M
,
Camisa
B
,
Barbiera
G
, et al
.
Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells
.
Nat Med
.
2018
;
24
(
6
):
739
-
748
.
4.
Giavridis
T
,
van der Stegen
SJC
,
Eyquem
J
,
Hamieh
M
,
Piersigilli
A
,
Sadelain
M
.
CAR T cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade
.
Nat Med
.
2018
;
24
(
6
):
731
-
738
.
5.
Park
JH
,
Nath
K
,
Devlin
SM
, et al
.
CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results
.
Nat Med
.
2023
;
29
(
7
):
1710
-
1717
.
6.
Kadauke
S
,
Myers
RM
,
Li
Y
, et al
.
Risk-adapted preemptive tocilizumab to prevent severe cytokine release syndrome after CTL019 for pediatric B-cell acute lymphoblastic leukemia: a prospective clinical trial
.
J Clin Oncol
.
2021
;
39
(
8
):
920
-
930
.
7.
Myers
RM
,
Li
Y
,
Barz Leahy
A
, et al
.
Humanized CD19-targeted chimeric antigen receptor (CAR) T cells in CAR-naive and CAR-exposed children and young adults with relapsed or refractory acute lymphoblastic leukemia
.
J Clin Oncol
.
2021
;
39
(
27
):
3044
-
3055
.
8.
Maude
SL
,
Frey
N
,
Shaw
PA
, et al
.
Chimeric antigen receptor T cells for sustained remissions in leukemia
.
N Engl J Med
.
2014
;
371
(
16
):
1507
-
1517
.
9.
Stevens-Jones
O
,
Mojzisova
H
,
Elisak
M
, et al
.
Paraneoplastic or not? sirtuin 2 in anti-N-methyl-d-aspartate receptor encephalitis
.
Eur J Neurol
.
2023
;
30
(
10
):
3228
-
3235
.
10.
Wang
H
,
Davison
MD
,
Kramer
ML
, et al
.
Evaluation of neurofilament light chain as a biomarker of neurodegeneration in X-linked childhood cerebral adrenoleukodystrophy
.
Cells
.
2022
;
11
(
5
):
913
.
11.
Kleinschmidt-DeMasters
BK
,
Gilden
DH
.
The expanding spectrum of herpesvirus infections of the nervous system
.
Brain Pathol
.
2001
;
11
(
4
):
440
-
451
.
12.
Jess
J
,
Yates
B
,
Dulau-Florea
A
, et al
.
CD22 CAR T-cell associated hematologic toxicities, endothelial activation and relationship to neurotoxicity
.
J Immunother Cancer
.
2023
;
11
(
6
):
e005898
.
13.
Nair
R
,
Drillet
G
,
Lhomme
F
, et al
.
Acute leucoencephalomyelopathy and quadriparesis after CAR T-cell therapy
.
Haematologica
.
2021
;
106
(
5
):
1504
-
1506
.
14.
Parks
NE
.
Metabolic and toxic myelopathies
.
Continuum (Minneap Minn)
.
2021
;
27
(
1
):
143
-
162
.
15.
Flanagan
EP
,
Keegan
BM
.
Paraneoplastic myelopathy
.
Neurol Clin
.
2013
;
31
(
1
):
307
-
318
.
16.
Alblas
CL
,
Bouvy
WH
,
Lycklama À Nijeholt
GJ
,
Boiten
J
,
Boiten
J
.
Acute spinal-cord ischemia: evolution of MRI findings
.
J Clin Neurol
.
2012
;
8
(
3
):
218
-
223
.
17.
Karschnia
P
,
Miller
KC
,
Yee
AJ
, et al
.
Neurologic toxicities following adoptive immunotherapy with BCMA-directed CAR T cells
.
Blood
.
2023
;
142
(
14
):
1243
-
1248
.
18.
Van Oekelen
O
,
Aleman
A
,
Upadhyaya
B
, et al
.
Neurocognitive and hypokinetic movement disorder with features of parkinsonism after BCMA-targeting CAR-T cell therapy
.
Nat Med
.
2021
;
27
(
12
):
2099
-
2103
.
You do not currently have access to this content.
Sign in via your Institution